Predictive Oncology Faces Competitive Challenges

Oncology tech company struggles to keep up with rivals in key metrics

Published on Feb. 22, 2026

Got story updates? Submit your updates here. ›

Predictive Oncology (NASDAQ:AGPU), a medical technology company focused on developing personalized cancer therapies, is facing challenges compared to its competitors in the 'Surgical, Medical, And Dental Instruments And Supplies' industry. The company lags behind its peers in areas like institutional ownership, insider ownership, gross revenue, earnings per share, net margins, return on equity, and return on assets.

Why it matters

As a smaller player in a competitive industry, Predictive Oncology's struggles highlight the difficulties it faces in standing out and gaining traction against larger, more established rivals. The company's weaker performance across key financial and operational metrics raises questions about its long-term viability and ability to effectively compete.

The details

Predictive Oncology has significantly lower institutional and insider ownership compared to the industry average, indicating a lack of confidence from major investors. The company also trails its competitors in terms of gross revenue, earnings per share, net margins, return on equity, and return on assets. Additionally, Predictive Oncology's stock is more volatile than the industry average, with a beta of 1.41 compared to 1.76 for its peers.

  • Predictive Oncology reported its latest financial results on February 22, 2026.

The players

Predictive Oncology

A medical technology company focused on developing personalized cancer therapies, operating in four segments: Helomics, zPREDICTA, Soluble, and Skyline.

Got photos? Submit your photos here. ›

The takeaway

Predictive Oncology's struggles to keep up with its competitors in key financial and operational metrics suggest the company faces an uphill battle in the crowded medical technology industry. The company's lower institutional and insider ownership, as well as its more volatile stock price, indicate a lack of confidence from major investors and raise questions about its long-term viability.